PMID- 29158791
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 8
IP  - 16
DP  - 2017
TI  - Correlation of cancer stem cell markers and immune cell markers in resected 
      non-small cell lung cancer.
PG  - 3190-3197
LID - 10.7150/jca.20172 [doi]
AB  - Background: Recent studies confirmed that immunotherapy showed prominent efficacy 
      in non-small cell lung cancer (NSCLC). Cancer stem cells/cancer initiating cells 
      are resistant to anticancer treatment. The purpose of the study was to analyze 
      the correlation of cancer stem cells/cancer initiating cells and 
      tumor-infiltrating immune cells in NSCLC. Methods: CD133, octamer 4 (OCT-4), CD8, 
      CD56, human leukocyte antigen (HLA) class I and programmed death ligand-1 (PD-L1) 
      were assessed in 172 resected NSCLC samples. The staining was analyzed and scored 
      by the pathologist who was blinded to the clinical pathological data of the 
      patients. Results: High CD8+ T cell infiltration was correlated significantly 
      with squamous cell carcinoma histology (p=0.008). High PD-L1 expression (>/=10%) 
      was associated with high tumor status (p=0.043). Pearson's correlation test 
      showed that CD56+ cells were negatively correlated with CD133 expression 
      (r=-0.361, p<0.001) and weakly correlated with negative OCT-4 expression 
      (r=-0.180, p=0.018). There was a strong positive correlation between CD8 and HLA 
      class I (r=0.573, p<0.001). In the survival analysis, high CD8+ T cell 
      infiltration is an independent predictor of improved disease-free survival and 
      overall survival. Patients with low CD133 expression and high CD56 expression had 
      a longer overall survival than those with high CD133 expression and/or low CD56 
      expression (p=0.013). Conclusion: There is a negative correlation between CD56+ 
      cells and cancer stem cell markers. This correlation may confirm the possibility 
      that natural killer cells can target CD133+ cancer stem cells/cancer initiating 
      cells in non-small cell lung cancer.
FAU - Huang, Zhaoqin
AU  - Huang Z
AD  - Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, Shandong, China.
FAU - Yu, Haining
AU  - Yu H
AD  - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Shandong Academic of Medical Science, Jinan, Shandong, China.
FAU - Zhang, Jianbo
AU  - Zhang J
AD  - Department of Pathology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Shandong Academic of Medical Science, Jinan, China.
FAU - Jing, Haiyan
AU  - Jing H
AD  - Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong 
      University, Jinan, Shandong, China.
FAU - Zhu, Wanqi
AU  - Zhu W
AD  - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Shandong Academic of Medical Science, Jinan, Shandong, China.
FAU - Li, Xiaolin
AU  - Li X
AD  - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Shandong Academic of Medical Science, Jinan, Shandong, China.
FAU - Kong, Lingling
AU  - Kong L
AD  - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Shandong Academic of Medical Science, Jinan, Shandong, China.
FAU - Xing, Ligang
AU  - Xing L
AD  - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Shandong Academic of Medical Science, Jinan, Shandong, China.
FAU - Yu, Jinming
AU  - Yu J
AD  - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Shandong Academic of Medical Science, Jinan, Shandong, China.
FAU - Meng, Xiangjiao
AU  - Meng X
AD  - Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong 
      University, Shandong Academic of Medical Science, Jinan, Shandong, China.
LA  - eng
PT  - Journal Article
DEP - 20170915
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC5665035
OTO - NOTNLM
OT  - CD133
OT  - CD8+ T cells
OT  - NK cells
OT  - Non-small cell lung cancer
OT  - OCT-4
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2017/11/22 06:00
MHDA- 2017/11/22 06:01
PMCR- 2017/01/01
CRDT- 2017/11/22 06:00
PHST- 2017/03/20 00:00 [received]
PHST- 2017/08/30 00:00 [accepted]
PHST- 2017/11/22 06:00 [entrez]
PHST- 2017/11/22 06:00 [pubmed]
PHST- 2017/11/22 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - jcav08p3190 [pii]
AID - 10.7150/jca.20172 [doi]
PST - epublish
SO  - J Cancer. 2017 Sep 15;8(16):3190-3197. doi: 10.7150/jca.20172. eCollection 2017.